Pasithea Therapeutics (KTTA) Return on Capital Employed (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Return on Capital Employed of 38.82% for Q1 2026, up 40.51% sequentially from 65.26% in Q4 2025, and up 6207.0% YoY from 0.62% in Q1 2025.
Pasithea Therapeutics (KTTA) Return on Capital Employed (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Return on Capital Employed for 6 years, with the latest figure at 38.82% in Q1 2026.
- Quarterly Return on Capital Employed rose 6207.0% year-over-year to 38.82% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 38.82% (up 6207.0% YoY) and the FY2025 annual result came in at 62.86%, up 849.0% from the prior year.
- Return on Capital Employed improved to 38.82% in Q1 2026 per KTTA's latest filing, from 65.26% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 12.29% in Q1 2022 and troughed at 100.89% in Q1 2025.
- A 5-year average of 60.65% and a median of 62.05% in 2023 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed sank 4755 bps in 2024, then jumped 6207 bps in 2026.
- Over 5 years, Return on Capital Employed stood at 33.5% in 2022, then plunged by 85 bps to 62.05% in 2023, then slumped by 41 bps to 87.79% in 2024, then increased by 26 bps to 65.26% in 2025, then jumped by 41 bps to 38.82% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 38.82%, 65.26%, and 99.41% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - | -45.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.82% |
| Dec 31, 2025 | -65.26% |
| Sep 30, 2025 | -99.41% |
| Jun 30, 2025 | -97.57% |
| Mar 31, 2025 | -100.89% |
| Dec 31, 2024 | -87.79% |
| Sep 30, 2024 | -92.28% |
| Jun 30, 2024 | -90.79% |
| Mar 31, 2024 | -77.11% |
| Dec 31, 2023 | -62.05% |
| Sep 30, 2023 | -49.17% |
| Jun 30, 2023 | -43.24% |
| Mar 31, 2023 | -38.70% |
| Dec 31, 2022 | -33.50% |
| Sep 30, 2022 | -24.34% |
| Jun 30, 2022 | -17.90% |
| Mar 31, 2022 | -12.29% |
| Dec 31, 2021 | -12.27% |